Alissa Tucciarone
Medical · New Hartford, NYNPI 1306453022
Payments from drug & device makers
Across 508 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Lilly USA, LLC$851
- Pfizer$803
- Biohaven Pharmaceutical Holding Company Ltd.$530
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,781100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 92 | $2,004 |
| AstraZeneca | 41 | $1,678 |
| Novo Nordisk | 81 | $1,587 |
| Lilly USA, LLC | 53 | $851 |
| Pfizer | 68 | $803 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $530 |
| Amgen | 21 | $478 |
| Bayer | 21 | $414 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $414 |
| GSK | 21 | $372 |
| Merck | 9 | $269 |
| Exact Sciences | 10 | $153 |
| EMD Serono, Inc. | 1 | $125 |
| LEO Pharma Inc. | 1 | $125 |
| Nevro Corp. | 2 | $109 |
| Tolmar, Inc. | 5 | $91 |
| Radius Health, Inc. | 3 | $68 |
| Boehringer Ingelheim | 3 | $65 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Amarin Pharma, Inc. | 3 | $59 |
| Lundbeck LLC | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 1 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Seqirus USA Inc | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Novartis | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Alk-abello, Inc | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,781 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $118,910 |
| EliquisApixaban | 89 | $73,779 |
| FarxigaDapagliflozin Propanediol | 52 | $48,623 |
| JardianceEmpagliflozin | 67 | $44,457 |
| XifaxanRifaximin | 12 | $43,052 |
| TrulicityDulaglutide | 27 | $33,260 |
| RybelsusSemaglutide | 16 | $22,264 |
| XareltoRivaroxaban | 26 | $19,980 |
| JanuviaSitagliptin Phosphate | 31 | $17,183 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,650 |
| TradjentaLinagliptin | 20 | $9,484 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,465 |
| VascepaIcosapent Ethyl | 23 | $8,526 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $6,681 |
| KerendiaFinerenone | 11 | $6,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,587 | $141,174112 claims |
| PfizerEliquis | $803 | $73,77989 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,678 | $58,08968 claims |
| Boehringer IngelheimJardiance, Tradjenta | $65 | $53,94187 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $414 | $43,05212 claims |
| Lilly USA, LLCTrulicity | $851 | $33,26027 claims |
| Johnson & JohnsonXarelto | $13 | $19,98026 claims |
| MerckJanuvia | $269 | $17,18331 claims |
| GSKTrelegy Ellipta | $372 | $11,65017 claims |
| BayerKerendia | $414 | $6,66211 claims |
| AbbVieSynthroid | $2,004 | $1,21137 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $23 | $84747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in New Hartford
- Lauren PlattNew Hartford$17K
- Austin PerryNew Hartford$17K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.